Targeting Bcl-xL for cancer treatment using a new degradation method
Inhibition of Bcl-xL by Targeted Degradation
This study is exploring a new way to treat certain types of cancer, like T-cell acute lymphoblastic leukemia, by using special molecules that can help break down a protein that makes cancer cells tough to kill, aiming to make treatments more effective and safer for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-10815549 on NIH RePORTER |
What this research studies
This research investigates a novel approach to cancer treatment by targeting the Bcl-xL protein, which is known to contribute to cancer cell survival and drug resistance. The study employs Proteolysis Targeting Chimera (PROTAC) technology to design small molecules that can selectively degrade Bcl-xL, minimizing toxicity to platelets while enhancing anti-tumor effects. By focusing on cancers like T-cell acute lymphoblastic leukemia (T-ALL), the research aims to improve treatment outcomes for patients who have limited options due to drug resistance. The approach is supported by promising preliminary results from mouse models that mimic human cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) or other cancers where Bcl-xL plays a significant role.
Not a fit: Patients with cancers not associated with Bcl-xL or those who are not eligible for experimental therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments with fewer side effects for patients.
How similar studies have performed: Other research has shown success with similar targeted degradation approaches, indicating potential for this novel strategy.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Zheng, Guangrong — University of Florida
- Study coordinator: Zheng, Guangrong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.